Evidence map›Paper›PMID 24050169›Full record

ReviewCurrent pharmaceutical design2014

Multiple hormonal dysregulation as determinant of low physical performance and mobility in older persons.

Marcello Maggio, Fulvio Lauretani, Francesca De Vita, Shehzad Basaria, Giuseppe Lippi, Valeria Butto, Michele Luci, Chiara Cattabiani, Graziano Ceresini, Ignazio Verzicco and 2 more

Abstract readReview
In one paragraph

Review in Current pharmaceutical design, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Effects of Vitamin D on Physical Function: Results From the STURDY Trial.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022
    Trial
  3. Article
  4. Review
  5. The treatment of chronic anemia in heart failure: a global approach.Clinical research in cardiology : official journal of the German Cardiac Society · 2024
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Age-Related Change in Mobility: Perspectives From Life Course Epidemiology and Geroscience.The journals of gerontology. Series A, Biological sciences and medical sciences · 2016
    Review
  14. Article
  15. Article
  16. INSULIN-LIKE GROWTH FACTOR-1 AND ANEMIA IN OLDER SUBJECTS: THE INCHIANTI STUDY.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2015
    Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marcello Maggio
Fulvio Lauretani
Francesca De Vita
Shehzad Basaria
Giuseppe Lippi
Valeria Butto
Michele Luci
Chiara Cattabiani
Graziano Ceresini
Ignazio Verzicco
Luigi Ferrucci
Gian Paolo CedaDepartment of Clinical and Experimental Medicine, Section of Geriatrics via Gramsci 14, 43100, Parma, Italy. marcellomaggio2001@yahoo.it.

Funding

The InChianti StudyZIAAG001050 · NIA · NATIONAL INSTITUTE ON AGING · PI FERRUCCI, LUIGI · 2009 to 2025
$2.1M
Intramural NIH HHS ZIA AG001050
6 · The paper itself

Abstract

Mobility-disability is a common condition in older individuals. Many factors, including the age-related hormonal dysregulation, may concur to the development of disability in the elderly. In fact, during the aging process it is observed an imbalance between anabolic hormones that decrease (testosterone, dehydroepiandrosterone sulphate (DHEAS), estradiol, insulin like growth factor-1 (IGF-1) and Vitamin D) and catabolic hormones (cortisol, thyroid hormones) that increase. We start this review focusing on the mechanisms by which anabolic and catabolic hormones may affect physical performance and mobility. To address the role of the hormonal dysregulation to mobility-disability, we start to discuss the contribution of the single hormonal derangement. The studies used in this review were selected according to the period of time of publication, ranging from 2002 to 2013, and the age of the participants (≥65 years). We devoted particular attention to the effects of anabolic hormones (DHEAS, testosterone, estradiol, Vitamin D and IGF-1) on both skeletal muscle mass and strength, as well as other objective indicators of physical performance. We also analyzed the reasons beyond the inconclusive data coming from RCTs using sex hormones, thyroid hormones, and vitamin D (dosage, duration of treatment, baseline hormonal values and reached hormonal levels). We finally hypothesized that the parallel decline of anabolic hormones has a higher impact than a single hormonal derangement on adverse mobility outcomes in older population. Given the multifactorial origin of low mobility, we underlined the need of future synergistic optional treatments (micronutrients and exercise) to improve the effectiveness of hormonal treatment and to safely ameliorate the anabolic hormonal status and mobility in older individuals.

Indexed as

Mobility LimitationPersons with DisabilitiesAgedAge FactorsAnabolic AgentsDisability EvaluationHormonesHumansRisk FactorsAnabolic AgentsHormones

Identifiers

PMID24050169
PMCPMC5155505

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.